Document Classification

Section Type: METHODS

Text: A total of 294 patients with axillary node-positive primary breast cancer of STAGE I-IIIa were randomly assigned to either CEF [cyclophosphamide (CPA) 500 mg/m (2) i. v. days 1 and 8 ; epirubicin (EPI) 60 mg/m (2) i. v. day 1 ; and 5-fluorouracil (5-FU) 500 mg/m (2) i. v. days 1 and 8] or CMF [CPA 500 mg/m (2) i. v. days 1 and 8 ; methotrexate (MTX) 40 mg/m (2) i. v. days 1 and 8 ; and 5-FU 500 mg/m (2) i. v. days 1 and 8].